药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Zuclopenthixol
Lanadelumab
The risk or severity of adverse effects can be increased when Lanadelumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Lecanemab
The risk or severity of adverse effects can be increased when Lecanemab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Fanolesomab
The risk or severity of adverse effects can be increased when Fanolesomab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Galcanezumab
The risk or severity of adverse effects can be increased when Galcanezumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Fremanezumab
The risk or severity of adverse effects can be increased when Fremanezumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Eptinezumab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Erenumab
The risk or severity of adverse effects can be increased when Erenumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Burosumab
The risk or severity of adverse effects can be increased when Burosumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Tildrakizumab
The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Besilesomab
The risk or severity of adverse effects can be increased when Besilesomab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Sulesomab
The risk or severity of adverse effects can be increased when Sulesomab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Emicizumab
The risk or severity of adverse effects can be increased when Emicizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Human cytomegalovirus immune globulin
The risk or severity of adverse effects can be increased when Human cytomegalovirus immune globulin is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Nebacumab
The risk or severity of adverse effects can be increased when Nebacumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Edrecolomab
The risk or severity of adverse effects can be increased when Edrecolomab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Bezlotoxumab
The risk or severity of adverse effects can be increased when Bezlotoxumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Olokizumab
The risk or severity of adverse effects can be increased when Olokizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Tregalizumab
The risk or severity of adverse effects can be increased when Tregalizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Racotumomab
The risk or severity of adverse effects can be increased when Racotumomab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Namilumab
The risk or severity of adverse effects can be increased when Namilumab is combined with Trastuzumab deruxtecan.